As generic versions of AstraZeneca’s blockbuster drug ticagrelor prepare to enter the market, The BMJ raises fresh concerns over the integrity of the clinical trials that underpinned its approval.

Fourteen years after AstraZeneca’s blood thinner Brilinta reached the market and now faces generic competition, the data that ...

The twice-daily pill is given to people with acute coronary syndrome -a sudden reduction of blood to the heart-reducing the ...

MEDICS have raised concerns over a drug taken by millions to prevent heart attacks and strokes, claiming key safety data was “misreported” by its manufacturer AstraZeneca.

The initial report of monotherapy with the BCL-2 inhibitor venetoclax showed it had durable clinical activity and favorable ...

The Ischemic Stroke Epidemiology Forecast Report 2025-2034 offers extensive analysis on prevalence trends and demographic influences of ischemic stroke globally. Covering eight key markets, it details ...

Drug delivery describes the method and approach to delivering drugs or pharmaceuticals and other xenobiotics to their site of action within an organism, with the goal of achieving a therapeutic ...

A new large-scale study has mapped the first molecular events that drive the formation of harmful amyloid protein aggregates ...

Supported by grants from the National Institutes of Health (HE 09070–05), the Veterans Administration and the New York Heart Association.